[Bilateral Choroidal Detachment and Hypotension Under Treatment with Checkpoint Inhibitors]

Overview

Journal Ophthalmologie

Specialty Ophthalmology

Date 2024 Sep 30

PMID 39347981

Authors

Jonathan Meinke

Maike S Adamson

Marlene Sassmannshausen

Thomas Ach

Frank G Holz

Matthias M Mauschitz

Affiliations

Soon will be listed here.

References

Tsai J, Lee J, Wang W, Zhang J, Cho H, Mamo S . Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008; 105(8):3041-6. PMC: 2268581. DOI: 10.1073/pnas.0711741105. View

Morante M, Pandiella A, Crespo P, Herrero A . Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Biomolecules. 2022; 12(11). PMC: 9687808. DOI: 10.3390/biom12111562. View

Plachouri K, Vryzaki E, Georgiou S . Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. Curr Drug Saf. 2018; 14(1):14-20. DOI: 10.2174/1574886313666180730114309. View

Schneider B, Naidoo J, Santomasso B, Lacchetti C, Adkins S, Anadkat M . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021; 39(36):4073-4126. DOI: 10.1200/JCO.21.01440. View

Martens A, Schauwvlieghe P, Madoe A, Casteels I, Aspeslagh S . Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect. 2023; 13(1):5. PMC: 9947214. DOI: 10.1186/s12348-022-00321-2. View

Acaba-Berrocal L, Lucio-Alvarez J, Mashayekhi A, Ho A, Dunn J, Shields C . Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment. JAMA Ophthalmol. 2018; 136(10):1205-1207. DOI: 10.1001/jamaophthalmol.2018.1851. View

Mihailovic N, Dyballa J, Herz S, Fluck M, Alnawaiseh M, Merte R . [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma]. Ophthalmologe. 2019; 117(5):467-471. DOI: 10.1007/s00347-019-00963-z. View

Liu Y, Chen Z, Qiu J, Chen H, Zhou Z . Altered Tim-1 and IL-10 Expression in Regulatory B Cell Subsets in Type 1 Diabetes. Front Immunol. 2022; 12:773896. PMC: 9231524. DOI: 10.3389/fimmu.2021.773896. View

Friedman C, Proverbs-Singh T, Postow M . Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016; 2(10):1346-1353. DOI: 10.1001/jamaoncol.2016.1051. View

10.

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C . Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(12):1217-1238. DOI: 10.1016/j.annonc.2022.10.001. View

11.

Dorfel D, Babst N, Heindl L, Kakkassery V, Muller M . [Staging and systemic treatment of ocular and periocular metastases]. Ophthalmologie. 2024; 121(5):374-381. DOI: 10.1007/s00347-024-02034-4. View